Newly Synthesized Imidazoline Compound Regulates Apoptosis and Toll-Like Receptor Signaling in Lung Adenocarcinoma and Normal Epithelial Cells
Open Access
- 30 September 2026
- journal article
- Published by Bingol Universitesi in Türk Doğa ve Fen Dergisi
- Vol. 15 (3) , 25-33
Abstract
Imidazoline is a heterocyclic compound with biological activity in regulating apoptosis, inflammation, and immune signaling. Lung cancer is a leading cause of cancer-related death, emphasizing the need for new therapies. This study examined the effects of imidazoline on apoptosis and Toll-like receptor (TLR) expression in A549 lung adenocarcinoma cells and Beas-2B normal bronchial epithelial cells. The chemical structure of the synthesized imidazoline was confirmed by FT-IR spectroscopy. Cells were treated with imidazoline, and expression of apoptotic markers (BAX, BCL-2) and TLR1-10 genes was analyzed. In A549 cells, imidazoline increased BAX and decreased BCL-2, indicating activation of intrinsic apoptosis and cell cycle arrest. Beas-2B cells showed the opposite pattern, suggesting selective toxicity toward cancer cells. Imidazoline also modulated several TLRs in both cell lines, highlighting potential immunoregulatory effects. These findings demonstrate that imidazoline promotes apoptosis and alters immune-related signaling in lung cancer cells without harming normal epithelial cells. This study is the first to report imidazoline’s impact on TLR expression in lung cancer, supporting its potential as a dual anticancer agent targeting both cell death and immune pathways.Keywords
Funding Information
- no
This publication has 34 references indexed in Scilit:
- Possible TLR-mediated immunostimulatory effect of Palbociclib in breast cancerMolecular Biology Reports, 2025
- Protective Effects of Quercetin Against Vincristine‐Induced Nephrotoxicity via Modulation of Oxidative Stress, Inflammation, and Apoptosis in RatsJournal of Biochemical and Molecular Toxicology, 2025
- Palbociclib Induces Apoptosis and Modulates Toll-Like Receptor Expression in Lung Adenocarcinoma and Epithelial CellsBratislava Medical Journal, 2025
- The imidazoline I2 receptor agonist 2-BFI enhances cytotoxic activity of hydroxychloroquine by modulating oxidative stress, energy-related metabolism and autophagic influx in human colorectal adenocarcinoma cell linesEuropean Journal of Pharmacology, 2025
- 18β-glycyrrhetinic acid Mitigates bisphenol A-induced liver and renal damage: Inhibition of TNF-α/NF-κB/p38-MAPK, JAK1/STAT1 pathways, oxidative stress and apoptosisFood and Chemical Toxicology, 2024
- Advances and challenges in the treatment of lung cancerBiomedicine & Pharmacotherapy, 2023
- Targeting cyclin‐dependent kinase 6 by vanillin inhibits proliferation of breast and lung cancer cells: Combined computational and biochemical studiesJournal of Cellular Biochemistry, 2021
- Toll‐like receptors (TLRs) in cancer; with an extensive focus on TLR agonists and antagonistsIUBMB Life, 2020
- Activation of imidazoline receptor I 2 , and improved pancreatic β-cell function in human isletsJournal of Diabetes and its Complications, 2018
- Biologically active compounds based on the privileged 2-imidazoline scaffold: The world beyond adrenergic/imidazoline receptor modulatorsEuropean Journal of Medicinal Chemistry, 2015